Ngs Testing News Today

Tina Cascone, MD, Ben Levy, MD, and Sandip Patel, MD, offer insights into the treatment approach in patients with unresectable early-stage NSCLC who are unsuitable for consolidation durvalumab or who progress on consolidation durvalumab.

Sandip Patel, MD, shares his expert perspectives on novel combination consolidation immunotherapy regimens that are under evaluation in unresectable early-stage NSCLC.

Expert panelists discuss the characterization of patients with unresectable, early-stage NSCLC and what their standard treatment approach is for this patient population.

Ben Levy, MD, reviews the 5-year update and clinical implications of the PACIFIC study which evaluated consolidation immunotherapy in unresectable early-stage NSCLC.

A panel of experts offers their insights into which patients with resectable early-stage NSCLC might be suitable for neoadjuvant versus adjuvant chemoimmunotherapy.

Shared perspective on the armamentarium of molecular testing assays in non–small cell lung cancer and how results can be best interpreted when selecting treatment.

Expert oncologists reflect on the current state of molecular testing in patients with non–small cell lung cancer and how it has impacted treatment pathways.

David Harpole, MD, discusses study design, results and clinical implications of the AEGEAN study of perioperative immunotherapy (neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in the treatment of early-stage NSCLC

A study presented at the American Society of Clinical Oncology Annual Meeting found practice- and provider-level racial and ethnic inequities in rates of next-generation sequencing (NGS) testing for patients with advanced non–small cell lung cancer (NSCLC) treated in the community setting.

Key opinion leaders in the field of non–small cell lung cancer management discuss the role of immunotherapy in patients with concomitant KRAS and KEAP1/STK11 mutations.